Price T Rowe Associates Inc. MD Sells 18,945 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Price T Rowe Associates Inc. MD reduced its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,215,438 shares of the biopharmaceutical company's stock after selling 18,945 shares during the period. Price T Rowe Associates Inc. MD owned about 1.02% of Catalyst Pharmaceuticals worth $25,367,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Susquehanna International Group LLP lifted its position in Catalyst Pharmaceuticals by 2.4% in the fourth quarter. Susquehanna International Group LLP now owns 99,213 shares of the biopharmaceutical company's stock valued at $2,071,000 after purchasing an additional 2,291 shares during the last quarter. Hsbc Holdings PLC raised its holdings in Catalyst Pharmaceuticals by 64.7% during the 4th quarter. Hsbc Holdings PLC now owns 36,337 shares of the biopharmaceutical company's stock valued at $764,000 after buying an additional 14,269 shares during the last quarter. State of Tennessee Department of Treasury boosted its position in Catalyst Pharmaceuticals by 4.5% during the 4th quarter. State of Tennessee Department of Treasury now owns 50,587 shares of the biopharmaceutical company's stock valued at $1,056,000 after buying an additional 2,193 shares during the period. Tower Research Capital LLC TRC grew its holdings in Catalyst Pharmaceuticals by 242.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 26,491 shares of the biopharmaceutical company's stock worth $553,000 after acquiring an additional 18,759 shares during the last quarter. Finally, MetLife Investment Management LLC increased its position in shares of Catalyst Pharmaceuticals by 6.9% in the fourth quarter. MetLife Investment Management LLC now owns 68,087 shares of the biopharmaceutical company's stock valued at $1,421,000 after acquiring an additional 4,413 shares during the period. 79.22% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. 10.40% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Trading Down 2.3 %

Catalyst Pharmaceuticals stock traded down $0.56 on Tuesday, hitting $23.74. 168,581 shares of the stock traded hands, compared to its average volume of 1,099,139. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.47 and a 1 year high of $26.16. The firm has a market cap of $2.89 billion, a P/E ratio of 20.19, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70. The business's fifty day simple moving average is $22.92 and its 200 day simple moving average is $22.35.

Analyst Ratings Changes

A number of research firms have recently weighed in on CPRX. Bank of America reiterated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Robert W. Baird lifted their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Stephens restated an "overweight" rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Catalyst Pharmaceuticals has an average rating of "Buy" and an average price target of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.